Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin add-on to propranolol for portal hypertension in liver cirrhosis with esophageal varices
2014-000102-35Phase 3Active
- Sponsor
- Clinica Medica 5
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of rifaximin in Portal Hypertension (PH), Cirrhosis and esophageal varices (2 arms), sponsored by Clinica Medica 5. Primary endpoint: Reduction of HVPG after 60 days. Started Oct 2014; status: active.
02
Drugs
rifaximin
03
Conditions
Portal Hypertension (PH)Cirrhosisesophageal varices
Beyond the preview
Go deeper on 2014-000102-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000102-35.